跳至主要内容
临床试验/NCT05662748
NCT05662748已完成不适用

Use of the Closure Device in Patient With Percutaneous Transfemoral Aortic Valve Replacement

RWTH Aachen University1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2020年1月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
250
试验地点
1
主要终点
Safety endpoints during index hospitalisation

研究概览

简要总结

Use of the closure device in patient with percutaneous transfemoral aortic valve replacement

详细描述

The advent of endovascular, transcatheter aortic valve replacement (TAVR), and mechanical circulatory support has offered new, minimally invasive therapeutic options that are rapidly becoming standard of care. These percutaneous transfemoral interventions require large-bore catheters and have created challenges for femoral arterial access management. Current approaches include surgical cut-down with arterial puncture under direct vision, and suture-based "pre-closure." Surgical cut-down is associated with longer procedural time, increased patient discomfort, deeper anesthesia, risk of wound complications including infection, and slower ambulation. The pre-closure technique overcomes many of the disadvantages of surgical cut-down but can be technically demanding, time consuming, and associated with a significant failure rate. Recent randomized TAVR trials have reported major vascular complications in 6% to 8% . Furthermore, a study on the 2 suture-based closure techniques for management of TAVR access reported a 20% vascular complication rate despite being used by experienced operators . Currently, the majority of access site complications result from failed arteriotomy closure . The percutaneous MANTA Vascular Closure Device (VCD) (Essential Medical Inc., Malvern, Pennsylvania) is a novel collagen-based technology dedicated to closure of largebore arteriotomies . The MANTA VCD underwent prospective multicenter evaluation for Conformitä Europäenne (CE) mark approval in the first detailed report of outcomes achieved with a dedicated large-bore vascular closure device Contrary to the aforementioned TAVR procedures, mechanical circulatory support therapy can be extended up to several days on the intensive care ward. Data on such delayed closure with is lacking. This registry is therefore aimed to document the initial experiences of delayed closure of a femoral large bore access with vascular closure devices in patients with an TAVR device.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient scheduled for treatment with the TAVR device
  • Decision to use the Manta or the Prostar closure device on a clinical base by the treating physician
  • Signed informed consent

排除标准

  • Male or female aged < 18
  • Pregnant and lactating females
  • Patient has been committed to an institution by legal or regulatory order

结局指标

主要结局

Safety endpoints during index hospitalisation

时间窗: 2018 - 2020

Major vascular complications,

Safety endpoints during index hospitalisation ( bleeding)

时间窗: 2018-2020

life-threatining-, major bleeding

Safety endpoints during index hospitalisation ( death )

时间窗: 2018-2020

death

次要结局

  • efficacy endpoints during index hospitalisation - (hemotasis)(2018-2020)
  • efficacy endpoints during index hospitalisation ( device failure)(2018-2020)
  • efficacy endpoints during index hospitalisation ( bail-out )(2018-2020)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jörg Schröder

PD Dr. med Jörg Schröder

RWTH Aachen University

研究点 (1)

Loading locations...

相似试验

Comparison Between Manta and Prostar Closure Devices | 临床试验